Does Rallies show 13F holders for BHC?

Yes. Rallies tracks hedge fund and 13F ownership data for BHC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BHC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BHC. It does not provide personalized investment advice.

BHC (Bausch Health Companies Inc) Stock Analysis - Hedge Fund Holdings

Bausch Health Companies Inc (BHC) is a publicly traded Healthcare sector company. As of May 21, 2026, BHC trades at $5.62 with a market cap of $1.99B and a P/E ratio of 13.20. BHC moved +3.48% today. Year to date, BHC is -25.68%; over the trailing twelve months it is +17.52%. Its 52-week range spans $4.25 to $9.85. Analyst consensus is neutral with an average price target of $7.00. Rallies surfaces BHC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BHC stock?

Hedge funds tracked by Rallies that own BHC include Icahn Carl, Rokos Capital, Glenview Capital, Oaktree Capital, and Bridgewater Associates. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bausch Health Companies Inc.

BHC Key Metrics

Key financial metrics for BHC
Metric	Value
Price	$5.62
Market Cap	$1.99B
P/E Ratio	13.20
EPS	$0.42
Dividend Yield	1.00%
52-Week High	$9.85
52-Week Low	$4.25
Volume	8
Avg Volume	0
Revenue (TTM)	$10.27B
Net Income	$120.00M
Gross Margin	0.00%

Top Hedge Funds Holding BHC

Icahn Carl holds 34.72M shares of BHC, changed +0.00% as of Jun 30, 2025.
Rokos Capital holds 1.37M shares of BHC, changed +0.00% as of Mar 31, 2024.
Glenview Capital holds 1.31M shares of BHC, changed +0.00% as of Jun 30, 2024.
Oaktree Capital holds 1.27M shares of BHC, changed +0.00% as of Dec 31, 2025.
Bridgewater Associates holds 670.37K shares of BHC, changed +36.97% as of Mar 31, 2026.

Latest BHC News

Bausch Health Q1 Revenues Jump 12% to $2.52B Despite $1.426B Impairment — Apr 29, 2026
Bausch Health Q4 Sales Rise 9% to $2.8B but Posts $112M Loss — Feb 23, 2026
Bausch Health's OraPharma Marks 25 Years of ARESTIN with Canada, Puerto Rico Expansion — Feb 19, 2026
Bausch Health Q4 Revenue Rises 9%, Cash Flow Drops $205M After Red Sea Trial Failure — Feb 19, 2026
Bausch Health Posts 9% Q4 Growth, Cuts $320M Debt, Sets 2026 Targets — Feb 19, 2026

Recent BHC Insider Trades

Lee Frank D. sold 24.46K (~$132.80K) on May 19, 2026.
Carson Seana sold 4.42K (~$25.50K) on Mar 3, 2026.
Carson Seana sold 6.86K (~$39.63K) on Mar 2, 2026.

BHC Analyst Consensus

6 analysts cover BHC: 0 strong buy, 0 buy, 5 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.00.

Common questions about BHC

Who owns BHC stock?: Hedge funds tracked by Rallies that own BHC include Icahn Carl, Rokos Capital, Glenview Capital, Oaktree Capital, and Bridgewater Associates. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bausch Health Companies Inc.
Does Rallies show 13F holders for BHC?: Yes. Rallies tracks hedge fund and 13F ownership data for BHC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BHC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BHC. It does not provide personalized investment advice.